Investigating exosomes in lung transplant recipients and their impact on graft dysfunction
Lung transplant recipient exosome phenotypes and the risk of primary graft dysfunction and acute lung allograft dysfunction
This study is looking at tiny particles called exosomes to see how they affect the immune system in people who have received lung transplants, with the goal of finding better ways to predict and manage complications after surgery, so that patients can receive more personalized care.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10892242 on NIH RePORTER |
What this research studies
This research focuses on understanding how exosomes, which are tiny vesicles released from cells, can influence the immune response in lung transplant recipients. By identifying specific biomarkers associated with primary graft dysfunction (PGD) and acute lung allograft dysfunction (ALAD), the study aims to improve risk stratification for lung transplant candidates. The approach involves analyzing exosome phenotypes from both donors and recipients to better predict complications that may arise after transplantation. This could lead to more personalized treatment strategies and improved outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are undergoing or have undergone lung transplantation and are at risk for primary graft dysfunction or acute lung allograft dysfunction.
Not a fit: Patients who have not received a lung transplant or those with conditions unrelated to lung transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the prediction and management of complications following lung transplantation, ultimately improving patient survival and quality of life.
How similar studies have performed: Previous research has shown promise in using biomarkers for predicting transplant outcomes, suggesting that this approach could lead to significant advancements in the field.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Mulligan, Michael Scott — University of Washington
- Study coordinator: Mulligan, Michael Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.